



8-11-06

1 hr /  
DAC /  
Box Seq

Express Mail No. EV903553232  
Date of Deposit: August 10, 2006

Attorney Docket No.: 02-06

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/616,560  
Confirmation No.: 2794  
Filing Date: July 9, 2003  
Examiner: Deepak R. Rao  
Group Art Unit: 1624  
Applicants: Mark Ledebor et al.  
For: INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)  
AND OTHER PROTEIN KINASES

**Certificate of Mailing Under 37 CFR §1.8**

I hereby certify that this correspondence and any documents referred to as attached hereto is/are being deposited with the U.S. Postal Service with sufficient postage as Express Mail in an envelope addressed to Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 10, 2006.

Susan Batty-Gunn

Typed or Printed Name

Susan Batty-Gunn

Signature

August 10, 2006  
Cambridge, Massachusetts

Mail Stop Petition  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Sir:

Transmitted herewith: [X] a Petition for Revival of an Application for Patent Abandoned Unintentionally Under 37 C.F.C. § 1.137(b); [X] a Reply to Office Action; [X] paper copy of Sequence Listing; [X] Computer Readable Form of Sequence Listing; [X] Statement Regarding Sequence Listing; [X] Copy of Notice to Comply; to be filed in the above-identified patent application.

Applicants:  
Application No.

Ledeboer et al.  
10/616,560

FEE FOR ADDITIONAL CLAIMS

- ☒ A fee for additional claims is not required.
- ☐ A fee for additional claims is required.
- ☐ A check in the amount of \$\_\_\_ in payment of the filing fee is transmitted herewith.
- ☐ Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

EXTENSION FEE

- ☐ The following extension is applicable to the Response filed herewith; ☐ \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); ☐ \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); ☐ \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- ☐ A check in the amount of ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00 in payment of the extension fee is transmitted herewith.
- ☐ Please charge the extension fee in the amount of ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.


Applicants:  
Application No.

Ledeboer et al.  
10/616,560

MISCELLANEOUS FEES

- [X] Please charge \$1,500.00 to Deposit Account No. 50-0725 in payment of Petition to revive unintentionally abandoned application (37 C.F.R. § 1.17(m)).


Respectfully submitted,



Karen E. Brown, Reg. No. 43,866

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483  
Customer No. 27916



<b>NOTICE TO COMPLY</b>	<b>Application/Control No.</b>	<b>Applicant(s)</b>	
	10/616,560	LEDEBOER et al	
	<b>Examiner</b>	<b>Art Unit</b>	
	Rao, D.	1624	

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: .

### Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

U.S. Patent and Trademark Office

Part of Paper No. 09062005